ACE and hypertensive nephropathy: Also, miRNAs could serve as modifiable treatment markers as ACE inhibitors or as a β-blocker treatment of hypertensive nephropathy patients with reduced miR-103a-3p and albumin-to-creatinine ratio [19,98].